

![]() |
Phase I trial of concomitant hyperfractionated radiotherapy with docetaxel and cisplatin for locally advanced head and neck cancer |
|
Authors | ||
Published in | The cancer journal. 2006, vol. 12, no. 1, p. 63-8 | |
Abstract | This study was conducted to determine the maximum tolerated dose of docetaxel when administered concomitantly with radical hyperfractionated radiotherapy and cisplatin in patients with locally advanced head and neck cancer. | |
Keywords | Aged — Antineoplastic Combined Chemotherapy Protocols/administration & dosage/adverse effects — Carcinoma, Squamous Cell/pathology/therapy — Cisplatin/administration & dosage/adverse effects — Combined Modality Therapy — Deglutition Disorders/etiology — Dose Fractionation — Dose-Response Relationship, Drug — Female — Head and Neck Neoplasms/pathology/therapy — Humans — Male — Maximum Tolerated Dose — Middle Aged — Mucositis/etiology — Neck Dissection — Neoplasm Staging — Taxoids/administration & dosage/adverse effects — Treatment Outcome | |
Identifiers | PMID: 16613664 | |
Full text | ||
Structures | ||
Research groups | Groupe Becker Minerva (imagerie ORL) (683) Groupe Dulguerov Pavel (ORL et chirurgie cervico-faciale) (145) La recherche translationnelle en oncologie (654) | |
Citation (ISO format) | ALLAL, Abdelkarim Said et al. Phase I trial of concomitant hyperfractionated radiotherapy with docetaxel and cisplatin for locally advanced head and neck cancer. In: The cancer journal, 2006, vol. 12, n° 1, p. 63-8. https://archive-ouverte.unige.ch/unige:33098 |